Darren Charlton Smith - 07 Sep 2026 Form 4 Insider Report for Telix Pharmaceuticals Ltd (TLX)

Reporting relationship: Group Chief Financial Officer
Issuer ticker: TLX
Reported as of: 07 Sep 2026
Net transaction value: +$19,998
SEC form: 4
Accepted by SEC: 14 Sep 2026, 19:20:14 UTC
Prior SEC filing: 01 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Oliver Newman, on behalf of Mr. Darren Smith, Group CFO

Key filing fact

Darren Charlton Smith filed Form 4 for Telix Pharmaceuticals Ltd (TLX) on 14 Sep 2026.

Key facts

This page summarizes Darren Charlton Smith's Form 4 filing for Telix Pharmaceuticals Ltd (TLX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 14 Sep 2026, 19:20.

Change

Previous filing in this sequence was filed on 01 Apr 2026.
Current net transaction value: +$19,998.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002122447 Primary reporting owner

Smith Darren Charlton

Relationship: Group Chief Financial Officer
Address: C/O TELIX PHARMACEUTICALS LTD, 55 FLEMINGTON RD, NORTH MELBOURNE, AUSTRALIA
Signature: /s/ Oliver Newman, on behalf of Mr. Darren Smith, Group CFO
Signature date: 14 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TLX transaction

Ordinary Shares

Purchase

Transaction value: $19,998
Shares: +2,071
Change %: +17%
Price: $9.66
Shares after: 13,992
Date: 07 Sep 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares purchased by the Reporting Person under the Employee Share Purchase Plan section of the Issuer's Equity Incentive Plan ("AU ESPP"), which shares were allocated on September 7, 2026, based on the Reporting Person's contributions to the AU ESPP from January 1, 2026 - June 30, 2026.

Footnote F2

Purchase price is recorded in Australian Dollars.